Frequency of CD8+ responders to EBV antigen stimulation
| . | LCL-responsive . | LMP2 pept-responsive . | BMLF1 pept-responsive . | |||
|---|---|---|---|---|---|---|
| Healthy donors . | Spots/106 CD8+cells (Mean ± SD)* . | % of CD8+ population . | Estimated Spots/106PBMC† . | Spots/106 PBMC (Mean ± SD) . | % of LCL-resp CD8+ cells . | Spots/106PBMC (Mean ± SD) . |
| EBV(+ve) HLA-A2 | ||||||
| ES | 954 ± 133 | 0.1 | 180 (18.9 ± 0.1%) | 27 ± 7 | 15.0 | 943 ± 154 |
| TF | 4 855 ± 1406 | 0.5 | 730 (15 ± 0.1%) | 11 ± 2 | 1.5 | 213 ± 41 |
| NE | 2 317 ± 145 | 0.2 | 199 (8.6 ± 0.4%) | 12 ± 1 | 5.8 | 138 ± 27 |
| TZ | 16 655 ± 2539 | 1.7 | 1577 (9.5 ± 0.5%) | 3 ± 0 | 0.2 | 57 ± 10 |
| FT | 37 830 ± 789 | 3.8 | 6545 (17.3 ± 1.8%) | 25 ± 1 | 0.4 | 641 ± 165 |
| SB | 3 721 ± 615 | 0.4 | 522 (14.0 ± 0.0%) | 63 ± 6 | 12.1 | 262 ± 12 |
| AL | 13 756 ± 2170 | 1.4 | 2553 (18.6 ± 1.2%) | 52 ± 4 | 2.1 | 126 ± 30 |
| MS | 4 565 ± 1322 | 0.5 | 607 (13.3 ± 0.6%) | 33 ± 6 | 5.5 | 174 ± 36 |
| TO | 17 705 ± 3514 | 1.8 | 2540 (14.3 ± 3.2%) | 32 ± 11 | 1.3 | 161 ± 35 |
| PG | 8 015 ± 733 | 0.8 | 560 (7.0 ± 1.4%) | 20 ± 0 | 3.6 | 13 ± 0 |
| GA | 20 961 ± 1472 | 2.1 | 2748 (13.1 ± 0.1%) | 83 ± 28 | 3.0 | 306 ± 36 |
| Average | 33 | 4.6 | 276 | |||
| EBV(+ve) non-A2 | ||||||
| JR | 10 197 ± 952 | 1.0 | 1977 (19.4 ± 0.6%) | 3 ± 1 | 0.1 | 0 ± 1 |
| ST | 33 822 ± 1616 | 3.4 | 3485 (10.3 ± 0.0%) | 1 ± 1 | 0.0 | 0 ± 0 |
| Average | 13 489‡ | 1.3† | 1863† | 2 | 0.1 | 0 |
| EBV(−ve) | ||||||
| PB | 813 ± 67 | 0.1 | 71 (8.7 ± 0.7%) | |||
| KR | 680 ± 103 | 0.1 | 102 (14.9 ± 0.1%) | |||
| DM | 1231 ± 165 | 0.1 | 241 (19.6 ± 2.2%) | |||
| Average | 908 | |||||
| . | LCL-responsive . | LMP2 pept-responsive . | BMLF1 pept-responsive . | |||
|---|---|---|---|---|---|---|
| Healthy donors . | Spots/106 CD8+cells (Mean ± SD)* . | % of CD8+ population . | Estimated Spots/106PBMC† . | Spots/106 PBMC (Mean ± SD) . | % of LCL-resp CD8+ cells . | Spots/106PBMC (Mean ± SD) . |
| EBV(+ve) HLA-A2 | ||||||
| ES | 954 ± 133 | 0.1 | 180 (18.9 ± 0.1%) | 27 ± 7 | 15.0 | 943 ± 154 |
| TF | 4 855 ± 1406 | 0.5 | 730 (15 ± 0.1%) | 11 ± 2 | 1.5 | 213 ± 41 |
| NE | 2 317 ± 145 | 0.2 | 199 (8.6 ± 0.4%) | 12 ± 1 | 5.8 | 138 ± 27 |
| TZ | 16 655 ± 2539 | 1.7 | 1577 (9.5 ± 0.5%) | 3 ± 0 | 0.2 | 57 ± 10 |
| FT | 37 830 ± 789 | 3.8 | 6545 (17.3 ± 1.8%) | 25 ± 1 | 0.4 | 641 ± 165 |
| SB | 3 721 ± 615 | 0.4 | 522 (14.0 ± 0.0%) | 63 ± 6 | 12.1 | 262 ± 12 |
| AL | 13 756 ± 2170 | 1.4 | 2553 (18.6 ± 1.2%) | 52 ± 4 | 2.1 | 126 ± 30 |
| MS | 4 565 ± 1322 | 0.5 | 607 (13.3 ± 0.6%) | 33 ± 6 | 5.5 | 174 ± 36 |
| TO | 17 705 ± 3514 | 1.8 | 2540 (14.3 ± 3.2%) | 32 ± 11 | 1.3 | 161 ± 35 |
| PG | 8 015 ± 733 | 0.8 | 560 (7.0 ± 1.4%) | 20 ± 0 | 3.6 | 13 ± 0 |
| GA | 20 961 ± 1472 | 2.1 | 2748 (13.1 ± 0.1%) | 83 ± 28 | 3.0 | 306 ± 36 |
| Average | 33 | 4.6 | 276 | |||
| EBV(+ve) non-A2 | ||||||
| JR | 10 197 ± 952 | 1.0 | 1977 (19.4 ± 0.6%) | 3 ± 1 | 0.1 | 0 ± 1 |
| ST | 33 822 ± 1616 | 3.4 | 3485 (10.3 ± 0.0%) | 1 ± 1 | 0.0 | 0 ± 0 |
| Average | 13 489‡ | 1.3† | 1863† | 2 | 0.1 | 0 |
| EBV(−ve) | ||||||
| PB | 813 ± 67 | 0.1 | 71 (8.7 ± 0.7%) | |||
| KR | 680 ± 103 | 0.1 | 102 (14.9 ± 0.1%) | |||
| DM | 1231 ± 165 | 0.1 | 241 (19.6 ± 2.2%) | |||
| Average | 908 | |||||
The mean and standard deviations are derived from results on two separate experiments; the results from each experiment represent the average of triplicate wells (or more than 12 wells in the case of LMP2 peptide-responsive CD8+ cells) with the same number of responders per well.
The frequency of LCL-responsive CD8+ cells is also presented as the number of spots/106 PBMC for comparison with peptide-responsive CD8+ cells. This is estimated by: (number of spots/106 CD8+ cells) × (% of CD8+ cells among PBMC). The percentage of CD8+cells among PBMC is obtained by positive selection of CD8+cells with Dynal-beads. The mean and standard deviation of 2 CD8+ cell selection are presented in parentheses.
This average is derived from both HLA-A2 and non HLA-A2 EBV (+ve) donors.